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Reply
Previously published results from the Heart Protection Study
(HPS) show clearly that lowering LDL cholesterol by about 1
mmol/L (38 g/dL) with simvastatin produced a highly significant
13% (SE 4) relative reduction in all-cause mortality (1328 [12.9%]
simvastatin-allocated vs 1507 [14.7%] placebo-allocated deaths; P
.0003) during the scheduled 5-year treatment period.1 This very
definite survival benefit reflected the combined impact of a highly
significant 17% (SE 4) relative reduction in vascular deaths (781
[7.6%] vs 937 [9.1%]; P .00001) and of a nonsignificant difference
in nonvascular mortality (547 [5.3%] vs 570 [5.6%]; P  .4). A
subsequent report showed that there were similar relative reductions
in vascular deaths (and nonfatal major vascular events), with no
evidence of any adverse effects on nonvascular deaths (or cancers), in
a range of different circumstances (including among women).2 The
reduction in vascular mortality started to emerge during the first year
of statin treatment and increased during each subsequent year of
treatment, with no adverse effect on nonvascular mortality emerging
during or after the scheduled treatment period.1-3
Meta-analyses of individual patient data from large random-
ized trials (including HPS) have reliably demonstrated that
statin therapy reduces vascular mortality substantially, while
producing little or no effect on nonvascular mortality.4 Conse-
quently, the relative reduction in all-cause mortality in some
particular circumstance is determined not only by the size of the
relative reduction in vascular mortality with statin therapy but
also by the ratio of vascular to nonvascular deaths. Moreover,
separate assessment of the effects of statin therapy on vascular
mortality and on nonvascular mortality in such circumstances
(considered in the context of the overall findings for cause-
specific mortality and for the much larger numbers of nonfatal
vascular and nonvascular events) is likely to provide a more
sensitive assessment of any benefits and hazards than would
direct comparisons of deaths from all-causes.
With regard to the subgroup of patients in HPS with
peripheral arterial disease (PAD), the observed 10% (95% CI
-5-12) relative reduction in vascular mortality (10.2% simvasta-
tin vs 11.2% placebo) was not significantly different from the
23% (12-32) relative reduction observed among the other high-
risk patients studied (heterogeneity P value  .1). Moreover,
this lack of heterogeneity of benefit with statin therapy was
reinforced by the similar (heterogeneity P value  .5), and
highly significant, relative reductions in major vascular events
(MVE): (ie, vascular deaths, heart attacks, strokes, and revascular-
izations) among patients with PAD (22% [SE 4]; P  .0001) and
the other high-risk patients (25% [SE 3]; P  .0001).5 The
apparent lack of effect on the small number of aneurysm deaths or
repairs should be considered in the context of these large reduc-
tions in vascular events. In terms of the absolute benefits in HPS,
allocation to statin therapy prevented 63 (11) first MVEs, and 116
(21) first and subsequent MVEs, per 1000 PAD patients. This
corresponds to a “number needed to treat” to prevent a first MVE
of 16 (SE 3), although this underestimates the benefit of actually
taking a statin because only about two-thirds of patients complied
with their allocated treatment during the 5-year study period. In
terms of safety, as was observed overall in HPS, there was no
apparent effect on nonvascular mortality among the patients with
PAD (7.3% simvastatin vs 7.7% placebo; hazard ratio 0.94; 95% CI
0.79-1.12; P  NS).
In conclusion,HPS has shown that 40mg simvastatin daily safely
reduces both vascular mortality and major vascular morbidity in
patients with PAD and in other high-risk patients, without adverse
effects on nonvascularmortality ormajor nonvascularmorbidity. It is,
therefore, entirely reasonable to conclude that vascular surgeons
should consider statin therapy for all patients with proven PAD
irrespective of age, gender, and baseline lipid levels.
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Regarding “Light assisted stab phlebectomy: Report
of a technique for removal of lower extremity
varicose veins”
In the article by Lawrence and Vardanian,1 the authors reported
on light assisted stab phlebectomy. I was amazed by how a simple
procedure can be made so eloquently complicated. We have per-
formed stab avulsion phlebectomies on more than 2000 patients in
our office without sedation. We use 1% local lidocaine anesthetic
injected only into the site of the 2 mm puncture over the previously
marked vein. Tumescent anesthesia is not required or used since we
find that it oozes from the incision making application of Steri-strip
closure unreliable. Provided that the vein itself is removed, without
any adjacent subcutaneous tissue, patients feel no pain. At most, they
notice a pulling sensation. Simple finger pressure for a minute or two
prevents bleeding even from a large varicosity.
No sutures are required to close the incision but simply
Steri-strips. We do not wrap the leg but rather use a 30 to 40 mm
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